# 21Shares XRP ETF: overview TOXR · CBOE · CIK 2028835 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/toxr.md) · [Financials](/companies/toxr/financials.md) · [Filings](/companies/toxr/filings.md) · [Insiders](/companies/toxr/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL not reported. ## Last five fiscal years | Line item | Unit | FY2025 (2025-12-31) | | --- | --- | ---: | | Revenue | $ | not reported | | Gross margin | % | not reported | | Operating margin | % | not reported | | Net margin | % | not reported | | Diluted EPS | $ per share | not reported | | Free cash flow | $ | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/toxr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $8.2m | 806,126 | | New +806,126 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $656.9k | 64,529 | | Reduced −36,118 | | [Teucrium Investment Advisors, LLC](/funds/2055352.md) | 2026-06-30 | $133.4k | 13,100 | | New +13,100 | | [Blue Trust, Inc.](/funds/1856022.md) | 2026-06-30 | $82.5k | 8,100 | | Unchanged | | [FLOW TRADERS U.S. LLC](/funds/1466697.md) | 2026-06-30 | $347 | 34,088 | | Reduced −50,092 | ## Recent filings [All 31 filings](/companies/toxr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-26 | 16:20 ET | [8-K](/filings/0001213900-26-093987.md) | 1.01 Entry into a material agreement; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-26-093987 | | 2026-08-11 | 16:35 ET | [10-Q](/filings/0001213900-26-087823.md) | Quarterly report, period 2026-06-30 | 0001213900-26-087823 | | 2026-07-07 | 16:31 ET | [8-K](/filings/0001213900-26-075988.md) | 1.02 Termination of a material agreement | 0001213900-26-075988 | | 2026-05-13 | 16:06 ET | [10-Q](/filings/0001213900-26-055788.md) | Quarterly report, period 2026-03-31 | 0001213900-26-055788 | | 2026-03-31 | 21:10 ET | [10-K](/filings/0001213900-26-036689.md) | Annual report, period 2025-12-31 | 0001213900-26-036689 | | 2026-01-26 | 16:05 ET | [10-Q](/filings/0001213900-26-007699.md) | Quarterly report, period 2025-09-30 | 0001213900-26-007699 | | 2025-12-08 | 06:14 ET | [S-1/A](/filings/0001213900-25-118924.md) | Registration statement, amended | 0001213900-25-118924 | | 2025-11-20 | 06:18 ET | [S-1/A](/filings/0001213900-25-112826.md) | Registration statement, amended | 0001213900-25-112826 | | 2025-11-07 | 17:00 ET | [S-1/A](/filings/0001213900-25-107665.md) | Registration statement, amended | 0001213900-25-107665 | | 2025-10-10 | 16:24 ET | [S-1/A](/filings/0001213900-25-098141.md) | Registration statement, amended | 0001213900-25-098141 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036689.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2028835 - Tickers: TOXR - Exchange: CBOE - SIC code: 6221 Commodity Contracts Brokers & Dealers - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.